Skip to content

Treating Cancer-Related Fatigue Through Systematic Light Exposure

Treating Cancer-Related Fatigue Through Systematic Light Exposure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01873794
Enrollment
54
Registered
2013-06-10
Start date
2012-01-31
Completion date
2014-07-31
Last updated
2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplantation, Breast Cancer, Fatigue, Mild Cognitive Impairment, Light, Quality of Life, Sleep

Keywords

Fatigue, Sleep, Quality of life, Cancer, Light

Brief summary

Cancer related fatigue (CRF) - a persistent sense of exhaustion related to cancer or cancer treatment - can severely interfere with activities of daily living, and has even been reported to be a factor in patient requests for hastened death. CRF can represent a serious clinical problem years after all treatment has ended. There is currently no effective treatment for CRF. The purpose of this study is to investigate whether systematic exposure to light (from a commercially available Litebook) reduces CRF or other symptoms.

Detailed description

Cancer related fatigue (CRF) - a persistent sense of exhaustion related to cancer or cancer treatment - can severely interfere with activities of daily living, and has even been reported to be a factor in patient requests for hastened death. CRF can represent a serious clinical problem years after all treatment has ended. In our research with cancer survivors 1 to 3 years after completion of hematopoietic stem cell transplant (HSCT), 40% of those we interviewed reported that CRF was a major obstacle to the resumption of usual activities. Despite its impact on quality of life, CRF is under-reported, under-diagnosed, and under-treated. A variety of pharmacologic agents have been studied to treat CRF, but there is insufficient evidence to recommend their use. The most promising non-pharmacologic interventions -- exercise and cognitive-behavior therapy (CBT) -- have shown equally modest effects. The proposed study focuses on a promising new intervention for CRF, using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box. Study collaborator, Ancoli-Israel and her colleagues have successfully piloted this line of research with breast cancer patients undergoing chemotherapy. The goal of this study will be to assess the effect of SLE on long-term HSCT and breast cancer survivors, and to determine the feasibility and acceptability of SLE as an intervention for CRF. The approach will be informed by the procedures that Ancoli-Israel and her colleagues developed for their research on SLE treatment for breast cancer chemotherapy, as well as by Redd's studies of CBT to treat adjustment disorders in survivors of HSCT. The study arms will test the efficacy of two different types of light treatment, bright white light and dim red light. Outcomes will be assessed through standardized measures of CRF, sleep quality, and quality of life.

Interventions

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of California, San Diego
CollaboratorOTHER
Hackensack Meridian Health
CollaboratorOTHER
Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients: * With a history of HSCT as treatment for hematological malignancies and related diseases and who are up to 3.5 years post-transplant; OR * Who are up to three and a half years post completion of chemotherapy OR chemotherapy and radiation for breast cancer with a curative intent; AND: * With a score equal to or less than 33 on the FACIT-Fatigue scale (see below) and no pre-existing anemia (Hb\<10gm/dl); or a score equal to or greater than 43 on the Cognitive Failures Questionnaire * Who are currently over age 18 and at least age 16 at the time of HSCT or time of breast cancer treatment

Exclusion criteria

* Under age 18; * Pregnancy; * Confounding underlying medical illnesses; * History of mania (which is a contra-indication for light treatment) or current clinical depression; * And any other physical or psychological impairments including a sleep disorder diagnosis which would limit participation.

Design outcomes

Primary

MeasureTime frameDescription
FACIT-Fatigue ScaleBaselineA list of statements that patients with cancer have said about their fatigue will be read. Subjects will mark on a 5-point scale how often they have felt each statement over the last 7 days. Measured at baseline, second week of light box use, fourth (last) week of light box use, three weeks post completion of light box use

Secondary

MeasureTime frameDescription
SF-36 ScaleBaselineQuality of life will be assessed using the SF-36 scale. The SF-36 is a multi-purpose, short form health survey consisting of 36 questions.
CNS-Vital SignsBaselineObjective cognitive function will be assessed using CNS-Vital Signs, a reliable and valid computer-administered cognitive assessment battery that consists of 7 cognitive tests.
The Pittsburgh Sleep Quality IndexBaselineThe validity of the instrument is based on its ability to discriminate patients (those having either sleep problems and/or depressive symptoms) from controls (healthy participants without sleep complaints). Baseline, second week of light box use, fourth (last) week of light box use, three weeks post completion of light box use
Brief Symptom Inventory-18BaselineUsed to assess psychological distress. A list of health problems and complaints that people sometimes experience are listed.
Actiwatch SpectrumBaselineSleep/wake activity is measured using an actigraph which records physical movement and detects light. The Actiwatch is worn for 72 consecutive hours.
The Cognitive Failures QuestionnaireBaselineA 25-item self-report measure of cognitive difficulties in everyday life using a 5-point Likert scale.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026